International Leukemia Target Board
Recruiting
Observational Study
Relapsed Hematologic Malignancy
Refractory Hematologic Malignancy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 0 – 25
- Sex
- Any
- Study type
- Observational
- Participants needed
- 600 (estimated)
- Sponsor
- Princess Maxima Center for Pediatric Oncology · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The iLTB is a proof-of-concept initiative for children with r/r hematological malignancies, in which available treatment options will be prioritized by actionable events in a harmonized and uniform setting across Europe by a team of biologists, bio-statisticians, bio-informaticians, disease experts, geneticists, flow-experts, clinical trial physicians and also the treating physician.
The iLTB wil…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion criteria
1. The patient has been diagnosed with a R/R hematological malignancy;
2. The patient is less than 18 years of age at the time of first diagnosis and less than 25 years at the time of inclusion with relapse/refractory hematological malignancy;
3. The patient is treated in a pedia…
Contacts